Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Tocilizumab (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 20 Jul 2018 New trial record